

SUSTAINABILITY REPORT 2023



We support life

www.macopharma.com

Table of contents

PDF INTERACTIF

#1

THE MACOPHARMA GROUP

- 1.1 Our business activities
- 1.2 Our markets
- 1.3 Multiple challenges and opportunities
- 1.4 Our corporate governance
- 1.5 Our stakeholders

#3

ENVIRONNEMENTAL INFORMATION

- 3.1 Climate change
- 3.2 Fight against pollution
- 3.3 Water and marine resources
- 3.4 Circular economy and waste management

#5

BUSINESS CONDUCT

- 5.1 Fight against corruption
- 5.2 Responsible purchasing

APPENDICES

- A_ ESRS Cross-reference table
- B_ HSE Policy
- C_ Ethical charter & code of good conduct
- D_ Declaration against modern slavery

#2

OUR CSR APPROACH

- 2.1 Governance and implementation
- 2.2 Materiality analysis
- 2.3 Impacts, risks and opportunities

#4

SOCIAL INFORMATION

4.1 Our employees

- 4.1.1 Overview of our employees
- 4.1.2 Social dialogue
- 4.1.3 Training and professional development
- 4.1.4 Health and safety
- 4.1.5 Quality of life at work
- 4.1.6 Equity, equal opportunity, inclusion
- 4.1.7 Fight against harassment and discrimination
- 4.1.8 Fair, adequate and attractive wages

4.2 The Group's role in the transfusion chain and its ecosystem

- 4.2.1 Innovative and effective healthcare solutions
- 4.2.2 Health education and support for healthcare professionals
- 4.2.3 Commitment to local stakeholders

4.3 Consumers and end-users

- 4.3.1 Patient health and safety
- 4.3.2 Continuous access for the greatest number of people

#1 THE MACOPHARMA GROUP

The Macopharma Group, founded in 1977 in Northern France, is the world's 3rd largest manufacturer of medical devices for blood treatment.



Key figures 2023



Human Resources

- **2166** employees worldwide
- **23** countries
- **43** nationalities



Sales

- **23 million** finished products
- **14** subsidiaries • **87** countries covered
- **70** distributors



Scientific

- **311** active patents • **225** brands
- **R&D investment:**
4% of total turnover



Production

- **3 plants:** France, Tunisia, Poland
- **20,3 million** of blood kits produced
Including **17,5 million of filters**
- **98%** our resources sourced in Europe

CERTIFICATIONS

- **ISO 14001:** Environmental management system
- **ISO 45001:** Occupational health and safety management system
- **ISO 22301:** Security and resilience – Business continuity management
- **ISO 13485:** Medical Device Quality Management

About this report

The European CSRD (Corporate Sustainability Reporting Directive) EU 2022/2464 of December 14, 2022, calls on companies to **increase transparency in their CSR approach and performance**, by publishing an annual report. In Macopharma's case, this requirement will be effective for the year 2026.


This report is therefore a **voluntary** reporting exercise. In it, Macopharma presents **its most material** environmental, social and governance issues, as well as the responses to them. The formalism of this document seeks to respond as closely as possible to the requirements of the CSRD, in order to prepare for it by 2026.

For most indicators, it covers 100% of the consolidated scope. Where this is not the case, the scope of the indicator is specified throughout the text.

#1.1

Our business activities

Macopharma's business is focused on blood transfusion, and in particular on kits for blood collection, leukoreduction and pathogen inactivation. This is organized around **"Blood Processing Solutions" (BPS)**, which represents all the stages between donor and patient, on which the company offers a range of blood processing solutions. Characterized by its expertise in medical devices, equipment, software and preparation processes, the Group's business aims to ensure the quality of blood collection and processing, to facilitate the practices of healthcare professionals and offer **safe blood components** to patients.



**1977**Foundation of
Macopharma**1980**First industrial
production of **blood
bags****1992**First industrial
production of
leukodepletion filters**1995**First subsidiary
in Germany**2002**Opening of
Macopharma plant
in Poland**2012**New production
site in Tunisia**2017****40 years**
dedicated to life**2020**Re-launch of
Protective Masks
activity

2023 News

• MacoSeal Light pre-launch

MacoSeal Light is a cordless sealer with long battery life, a uniquely compact and lightweight design, and an intuitive sealing button for all operating configurations. The MacoSeal Light's design has been conceived to increase the machine's capabilities while optimizing ergonomics and reducing manual effort.

See also section 4.2.1.



- **Launching operational excellence**

Given Macopharma's challenges and ambitions for the coming years, the Group has chosen to transform itself methodically by launching its 5-year Operational Excellence plan.



- **Transition to Non-DEHP:**


Macopharma is continuing its drive to switch all its products to Non-DEHP in line with REACH regulations. Numerous scientific studies have enabled us to build our solution: DEHT x PAGGS-M.

See section 4.3.1



- **Automation and robotization :**



Macopharma is equipping itself with tools to modernize its infrastructures and meet tomorrow's production challenges, while guaranteeing the quality and durability of its products.



#1.2

Our markets

The Macopharma Group achieved consolidated sales of **170 million euros in 2023, in over 87 countries, through 14 sales subsidiaries and a network of over 70 distributor partners**. This makes Macopharma the world's 3rd-largest player in the field of blood-based medical devices.



Revenue models, marketing methods and distribution channels

Most of the Group's customers are **blood banks**, which may or may not be part of hospitals. The organization of the corresponding blood supply chain may be **public** (centralized or decentralized) or **private**, depending on the country, for example:

→ **Public:**

- Centralized: France (EFS), England (NHS BT), Australia (Life Blood)
- Decentralized (regional level): Germany (DRK)

→ **Private:** Vitalant (USA), Einstein Hospital (Brazil), Emag Ag (Germany)

Its business model operates mainly on **multi-year tenders** (4 to 5 years). 63% of its sales (106 million Euros) are generated by direct sales through the head office (France) and 14 sales subsidiaries (Canada, USA, Germany, Italy, Spain, Benelux, Poland, Switzerland, Middle East, Australia, Brazil, Scandinavia, UK, Tunisia). The remaining 37% of sales are made through our network of 70 distributors in over 70 countries worldwide.

#1.3

Multiple challenges and opportunities

Macopharma is driven by **its vision**: "We make the best out of every drop of blood by providing sustainable solutions to every patient". As a global player in the healthcare field, the Group faces a number of contemporary challenges and/or challenges specific to its activities.

Innovation

Our challenge

Innovation is a key differentiating factor for Macopharma. It not only enables us to provide solutions that meet our customers' needs and requirements as closely as possible, it also enables us to assume our role as a major player, pioneering and promoting ever more reliable and sustainable solutions. This culture of innovation enables us to generate new market opportunities, adapt to a constantly changing world, and increase Macopharma's positive impact on its ecosystem.

Our response

Macopharma develops a culture of innovation and guarantees its level of expertise by continuously investing in Research and Development (R&D). By 2023, this investment represented 4% of turnover, with 311 active patents and 225 active trademarks.

See also section 4.2.1

Quality

Our challenge

Operating within the blood industry, Macopharma is responsible for sustaining the life and ensuring the safety of the patient, the end-user of its products. To achieve this, the company must maintain a high level of quality in the design and manufacture of its solutions.

Our response

Macopharma has set itself the objective of meeting regulatory and normative requirements in this field, while understanding and anticipating customer needs, both in terms of products and services. As a result, the company is organized around the safety of its products, and constantly monitors to ensure compliance.

Compliance with normative and regulatory requirements is the foundation of all the company's actions. Macopharma has developed a structured quality management system, which applies to all the company's audited and ISO 13485 certified sites and subsidiaries. This absolute priority goes hand in hand with a positioning that implies constant attention and anticipation of customer expectations.

See also section 4.3.1

Continuity of solutions

Our challenge

As blood products are irreplaceable in the support of countless medical procedures and the treatment of pathologies, every link in the transfusion chain is essential. Given its position in the transfusion chain, Macopharma must ensure the continuous production and distribution of its solutions. It should be noted that some customers have Macopharma as their sole supplier, and that business continuity in the delivery of its solutions is essential.

Our response

Macopharma manages its business continuity through an ISO 22301-certified management system. During 2023, the company recorded several declarations of events that could have an impact on its business continuity. The management of these events, in line with the organization set out in the business continuity plan (BCP), enabled us to contain the effects internally, without any direct impact on our customers, thanks to action and mitigation plans for potential consequences.

See also section 4.3.2

Digital security control

Our challenge

Cybersecurity is a growing challenge for all companies, a battle shared by all. The ever-changing technological environment, the interconnection of information systems and the proliferation of malicious acts are all challenges that require organizational, technical and legal responses.

Our response

Macopharma deploys a culture of security supported by tools and the involvement of everyone. Its technical and organizational tools are continuously adapted to the latest cyber-security threats. They enable us to proactively collect, analyze and monitor alerts and attack signals.

100% of connected objects are protected by security applications. In 2023, Macopharma joined the list of companies that have signed the [Cyber Charter](#) and is committed to respecting its 8 commitments. Raising employee awareness is also a key element of digital security. It is deployed both through training, the sharing of best practices, appropriate communication devices and during the annual "Cyber Security Month" highlight.

→ 196 employees trained in cyber security in 2023.

Corporate social responsibility

Our challenge

The world is facing profound environmental and social changes: climate change, resource management, but also expectations in terms of quality of life at work, fairness and business ethics are challenging companies to adapt their business model and strategy to ensure their sustainability.

Our response

As a company serving life, Macopharma assumes its responsibilities in 3 critical dimensions: the products and services it provides, the people it works with, and the planet it respects. In 2023, the company structured its “Ambition 2030” approach around its mission “Blood is life, we support life”. The results of its actions and commitments are described throughout this report.

#1.4

Our corporate governance

In 2022, Macopharma’s corporate governance was restructured in line with best practice, advocating the separation of powers between a Chairman of the Board of Directors and a Managing Director of the Executive Committee (EXCOM).

The Chairman of the Board validates the company’s strategic decisions (orientations, decisions with significant financial implications, etc.) proposed by the Executive Committee. **The Managing Director** oversees the implementation of strategic orientations, in collaboration with the Executive Committee.

The Board of Directors is made up of one woman and four men, drawn from the textile and food retailing, food processing and medical device industries. They bring their complementary expertise and experience to support Macopharma in its strategy. In 2023, this same board validated the company’s “Ambition CSR 2030” approach, based on the stakeholder consultation (materiality matrix) carried out in 2022, and will monitor progress on these issues once a year.

The Executive Committee comprises three women and five men. Its members head Macopharma’s functional departments, reflecting its organization.

EXCOM members contributed to structuring the CSR Ambition. 5 of them have followed specific training.



Caroline HERNU
Managing Director



Frank SCHOENFELD
Blood Processing
Solutions Director



Isabelle ROHAN
Head of Human Resources and
Sustainable Transformation



Thomas WIDMAIER
Head of Finance



Raouf BENYAMINA
Regulatory Affairs, Quality
and Materiovigilance
Director



Sabine BOUTONNET
Operations Support
Director



Sergio PIZZOFERRATO
Head of Manufacturing

#1.5

Our stakeholders



#2 OUR CSR APPROACH

Highlights



CSR Approach

M.A.C.O Values

For almost 50 years, Macopharma has been building, and continues to evolve, in a complex and changing world. Against this backdrop, the Group and its employees are supported by the foundations of the company: its values, M.A.C.O.

Being M.A.C.O means :

Move with agility

Develop your creativity, your ability to step back, challenge yourself and simplify processes to facilitate change.

Anticipate

Be open to new things, innovate, but also analyse before acting and plan to anticipate future needs.

Create value


Act by creating value for all stakeholders, results and a positive impact to support a sustainable business model.

One Maco

Working together, showing solidarity, developing ourselves and others to achieve common goals.

These foundations support Macopharma's strategic house, with its vision and mission as its roof, and the pillars that represent its roadmap as its walls: life, solutions and learning.

Macopharma Strategic House





Engaged for life

The company's CSR approach is at the heart of this house, within the “engaged for life” pillar, and this through four axes: **governance, people, planet and patients**. These pillars reflect the idea that the company's health depends on the health of the men and women it works with, of the planet, of the patients and of its entire ecosystem (“**One Health approach**”). The 2030 ambition represents the Group's medium-term CSR roadmap, **structuring its CSR orientations**. Each axis is also linked to the **UN's Sustainable Development Goals (SDGs)**, concretizing Macopharma's commitment to contributing to a more sustainable world.

Finally, this ambition has been designed by taking into account the **opinions of its stakeholders**, following the prioritization of CSR issues in its materiality matrix (see section 2.2).

CSR 2030 Ambition



#2.1

Governance and implementation

System

As of 2022, the **Group's Human Resources and Sustainable Transformation Director** is responsible for **steering the approach and structuring** the Group's CSR strategy. The HR and CSR teams have been grouped under a single management team, in order to **work on cross-functional issues**: operational implementation of actions, raising employee awareness and developing "sustainable leadership".

Raising employee awareness

To be a sustainable and responsible company, you also need to make the people who make up the company aware of their **responsibilities**. To this end, Macopharma is working to raise its employees' awareness of the various issues, in order to inform them but also, ultimately, to **give them the means to play their part in the transition**.

Training

It was with this in mind that the "CSR training days" were deployed. In 2023, each employee has taken, or will in 2024/2025, a **full day's training to understand the social, environmental and societal issues** facing Macopharma as a company, but also those facing us all as citizens.

During the day, each participant takes part in the **Climate Fresk** workshop, to discover or deepen their knowledge of the cause-effect links of **climate disruption**. The day then continues with a focus on understanding the **principles of CSR**, and how they fit into the company's actions, to better grasp Macopharma's ambition and its implications for day-to-day work.

Composition of CSR training days



→ 270 people trained by 2023.

12,5%
in 2023

2030 Objective : 100%
of our collaborators trained in CSR

CSR ambassadors

With a view to deploying this training plan, the Group has also identified CSR ambassadors **at its production sites and subsidiaries**. Having all volunteered to join the program, the team of ambassadors comprises **20 people**, including 12 women and 8 men. 13 of them belong to the French site, 3 to the Polish site, 3 to the Tunisian site and 1 to the German subsidiary.

Their first mission is to **lead CSR training days** (a minimum of 2 days each in 2023 and 4 in 2024), but also to act as a **communication link** in their work environment, to stimulate the flow of information and ideas. A new call for volunteers is planned for 2024.

2030 Objective :
identify CSR ambassadors at all our sites

100% of target achieved in 2023

Internal and external communication

Employee awareness is also raised through internal communications using a variety of media: posting of the company's carbon footprint and internal news, distribution of external societal news, articles in the in-house newsletter, as well as the various events described in sections 4.1.4, 4.1.6 and 4.1.7.

As far as external contacts are concerned, our actions have been promoted for several years through **the voluntary publication of a CSR report** (formerly a sustainable development report) on the company's website, a dedicated CSR web page on the latter, publications on social networks and the promotion of our CSR approach at conferences and forums.

#2.2

Materiality analysis of ESG issues¹

Stakeholder consultation - strategic materiality analysis

To build its CSR Ambition for 2022, Macopharma carried out an in-depth analysis of its **strategic CSR challenges**, in line with the recommendations of the international GRI reference framework.

In this first stage, the working group, made up of managers and EXCOM members, identified a set of 43 issues drawn from:

- ISO 26000,
- GRI guidelines,
- the 10 principles of the Global Compact,
- OECD guidelines for multinational enterprises,
- the 17 UN Sustainable Development Goals,
- issues specific to the blood processing solutions industry,
- and DPEF regulations.

¹ Environmental, Social and Governance criteria. ESG criteria are the criteria by which Macopharma reports on its CSR approach.

² Global Reporting Initiative.

These 25 issues were then **assessed** by a panel of internal and external stakeholders, in a wide-ranging **consultation** carried out by an independent external consultancy, based on questionnaires and interviews.

Internal stakeholders: employees, EXCOM members and members of the Board of Directors (including 9 interviews).

External stakeholders: blood banks and hospitals, institutions, suppliers and subcontractors, industrial partners, members of civil society (including 30 interviews).

The 290 respondents **prioritized** the 25 issues by answering the question “From your point of view and in light of your expectations, is this issue important for Macopharma?”

This consultation enabled us to gather a large amount of qualitative information and establish a new mode of dialogue with the Group’s stakeholders.

Double materiality analysis - CSRD regulation

In 2023, the Group wished to **continue this analysis work**, as part of the publication of this 2023 Sustainability Report, based on the European Sustainability Reporting Standards (ESRS) published in July 2023, and on the Double materiality conceptual guide for standard setting, published in January 2022 by EFRAG³.

To this end, the EXCOM, in collaboration with the CSR team and an external consultancy, drew on the lessons learned from the 2022 consultation.

As a first step, the working group compared the results of the strategic materiality analysis with the list of ESG issues defined by the ESRS1 standard. This initial analysis was used to verify the **correspondence between the strategic CSR issues and the issues listed in the ESRS**.

Then, the members of the working group rated the materiality of each issue according to the methodology published **by EFRAG**:


- Consideration of the **value chain** (tier 1 suppliers, customers, distributors and end-users);
- **Forward-looking approach** (short term <1 year, medium term 1 to 5 years, long term > 5 years);
- An approach consistent with **risk** analysis but enriched by **opportunity** analysis;
- **Impact materiality** assessment criteria: severity (importance, extent, possibility of remediation), probability of occurrence
 - Scoring: Critical, Important, Informative, Minimal;
- **Financial materiality** assessment criteria: importance of potential financial effects, probability of occurrence
 - Risk scoring: Critical (requiring strong mitigation), Important (with permanent mitigation measures), Low (acceptable), Not a risk
 - Opportunity scoring: Existence of business opportunities, no business opportunity.

This work enable us to review the Group’s CSR strategy in detail, by re-examining, for each issue, **Macopharma’s actual or potential impact on third parties and the environment**, and the **risks and opportunities of the issue for the Group’s financial performance**.

The result of **the rating of issues** is shown below in a **double materiality matrix**. The rating of the risks, impacts and opportunities of each issue also appears in the introduction to each section of this report.

³ EFRAG is a European advisory group on financial and non-financial reporting, responsible for defining the application of the CSRD.

DOUBLE MATERIALITY Of the 21 issues evaluated material (September, 2023)



#2.3

Summary of material issues: impacts, risks and opportunities

ESG criteria	ESRS	Issue	Impact	Risks (actual or potential)	Opportunity
Environment	E1 - Climate change	Combating climate change	GHG emissions from operations	Regulatory, tax and environmental costs	A differentiating factor in customers' tenders
		Adapting to climate change		Access to resources and continuity of industrial activity	
		Energy management	GHG emissions from consumption	Rising energy prices	
	E2 - Pollution	Pollution of air, water, soil, living organisms and food resources	Production of plastic and chemical waste during the industrial process	Financial consequences and employer brand if an industrial incident occurs	
		Substances of very high concern, extremely high concern, microplastics	Use of substances listed in the REACH regulation	Regulatory, compliance and regulatory monitoring costs, risk of loss of right to practice in the event of non-compliance	Developing innovation capacity to anticipate regulations
	E3 - Water and marine resources		Moderate water consumption in product formulation and sterilization	Risk of production interruptions in case of water stress	
	E5 - Resource use and circular economy		Production of single-use solutions	Rising raw material costs, access to resources	Partnerships to find solutions for industrial waste treatment and recycling, innovation in eco-design

ESG criteria	ESRS	Issue	Impact	Risks (actual or potential)	Opportunity
Social and societal	S1 - Own workforce - Working conditions	Health & Safety	Risks of work-related accidents and MSD/ occupational illnesses	Costs related to accident/occupational illness prevention and management, absenteeism and social climate	
		Quality of life at work	Employee well-being	If QWL is poor: absenteeism and loss of commitment, loss of attractiveness	
		Social dialogue	Opportunity to express employee concerns and needs	If social dialogue is lacking: risk of tension and conflict	
		Adequate wages, job security	Decent wages and benefits	Job market tension, attractiveness & talent retention	
	S2 - Own workforce - Equal treatment and opportunities for all	Fairness, equal treatment and opportunities for all	Major factors in workplace well-being and career development		Development of systems to ensure social progress and equal treatment
		Fighting harassment and discrimination		Employer brand risk in cases of harassment and discrimination	
		Diversity, inclusion & disability			Recognition by local partners
	S3 - Assigned communities	Open innovation	Enhanced capacity for innovation	Loss of competitiveness and efficiency of solutions	Product co-development, a growth driver
		Health education	Proper use of devices by healthcare professionals, dissemination of scientific knowledge		Giving meaning & brand image
		Commitment to local players	Positive societal impact on health, training and professional integration		Local implementation
	S4 - Consumers and end users	Health & Safety	Patient health and safety	Reputational and licensing risk	
		Continuous access to solutions	Continuous availability of products and solutions	Commercial risk	
Governance	G1 - Business conduct	Fighting corruption	Business ethics and compliance	Reputational, commercial and legal risk	
		Responsible purchasing	Respect for human rights, social rights and environmental regulations	Emerging reputational and legal risk (law on duty of care)	

#3

ENVIRONMENTAL INFORMATION

The environment is an integral part of Macopharma's CSR strategy. This "planet" pillar is made up of three guidelines:

- the carbon trajectory;
- the use of natural resources and the circular economy;
- the development of sustainable products through innovation.

The "planet" pillar is steered by the **CSR Director**, with the support of the **Group's operational** and **corporate** teams. The company has formalized its approach, notably through its **HSE (Health, Safety and Environment) policy** [see appendix B] and an **ISO 14001-certified Environmental Management System (EMS)**.

According to the materiality analysis, all ESRS-E standards have been identified as material, with the exception of ESRS E4 relating to biodiversity and ecosystems. As the company's activities are not directly linked to the exploitation of soil or any other ecosystem, and its waste or end-of-life products are mostly recycled or destroyed, it was decided to deal with the issue through ESRS E2, relating to pollution (see section 3.2).

#3.1

Climate change

ESRS
=
E1

CONTEXT AND ISSUES

Climate change is already affecting all human activities, and recent IPCC reports underline the urgency of **taking action to try to slow its effects**. More and more companies are aligning their strategies to **contribute, to the extent of their impact**, to limiting global warming to below 1.5°C, and thus collectively achieving the objectives of the **Paris Agreement**.

This decarbonization strategy largely involves **controlling greenhouse gas (GHG) emissions and energy consumption**, particularly in the industrial sector.

Climate risk management consists of a number of initiatives designed to increase the Group's **resilience** and ensure the **continuity of its operations** over the long term.

◦ *Combating climate change*

Macopharma **calculated its carbon footprint for the first time** in 2022, using data from 2021, **for scopes 1, 2 and 3**. The exercise was repeated for the years 2022 and 2023. This work showed that the most significant emission items, the impact of direct purchases (raw materials) and the end-of-life of products sold (mainly single-use blood bag kits), account for more than half of the Group's carbon impact. However, the essential role played by blood bags in the transfusion chain places **heavy regulatory and health constraints** on them. In this respect, the scope for reducing their impact on the climate is currently limited. On the other hand, it should be emphasized that the severity of the Group's climate impact is not considered critical, **with a carbon intensity of around 282.5t CO₂e /million euros of turnover** for the year 2023.

Climate change could **entail several types of costs** for the company, such as: regulatory or tax costs, due to increasingly stringent climate legislation; higher energy costs. However, the Group's commitment to combating climate change enables it to **meet the growing expectations of its customers**. Climate change is becoming an increasingly important factor in calls for tender.

◦ Adapting to climate change

The assessment of **natural risks** (floods, earthquakes, storms, etc.), which may evolve in line with climate change, is part of the company's **industrial risk mapping** (risk and business continuity register) and constitutes an input element for the **business continuity plans** of each site. Recent heat waves have increased the need for air-conditioning and could have an impact on the **availability of water**, specifically for the Tunisian site, which is taken into account in the continuity plans. As water is essential for manufacturing and sterilization processes, this represents a business continuity risk. It should also be noted that the climate could, in the long term, have consequences for **working conditions** in certain positions. Macopharma must therefore master this risk and be able to implement **adaptation measures**.

◦ Energy management

The **Group's commitment to reducing emissions** is largely achieved through energy efficiency and energy recovery initiatives (scopes 1 & 2). These actions enable the Group to strengthen its energy autonomy and thus gain better control over the associated financial and climatic costs.

COMMITMENTS

Macopharma is committed to following a carbon trajectory in order to contribute to the global effort to combat climate change. This is illustrated by three commitments in its ambition 2030:

- Reduce our carbon emissions to contribute to the Paris Agreement
- Optimize the use of natural resources
- Develop sustainable products

[Reminder of 2030 objectives]

- 30% reduction in GHG emissions linked to our activities (scope 1 & 2), on a like-for-like basis
- 5% annual reduction in energy consumption, like-for-like
- 100% of our product range is subject to an environmental life cycle analysis

ACTION PLANS

1 - Define a detailed carbon trajectory

Since 2022, with data from 2021 (base year), Macopharma has committed to assessing its carbon footprint each year on the 3 scopes and applying the **GHG Protocol methodology**.

In 2023, Macopharma's carbon footprint amounted to **48,050 tonnes of CO2 equivalent**, representing a carbon intensity of 282.5t CO2e /million euros of turnover.

Apart from the impact of products' end-of-life, the **4 most significant emission items** are: raw materials purchases, waste (linked to production), energy consumption on scopes 1 and 2, and freight. Raw materials have a direct impact on product end-of-life.

On this basis, in order to **reduce the company's carbon impact** on a like-for-like basis, several study projects identified and begun in 2022, have been continued into 2023:

- Deployment and implementation of the first 3-year energy consumption reduction plan (see details below).

- Systematic integration of environmental criteria (and more specifically the carbon footprint) into projects, developments and modifications. For major projects, the result of the environmental impact could be one of the decision-making criteria;
- Training and awareness-raising plan for employees on the climate fresh, actions and commitments that can be taken to reduce the carbon footprint at individual and collective level (see section 2. 1);
- Adaptation of supply chain flows to reduce the impact of freight, in conjunction with purchasing strategy and industrial organization;
- Inclusion of environmental requirements in contracts with carriers;
- Development of partnerships with certain raw materials suppliers to define common reduction targets (see section 3.4);
- Launch of eco-design projects for our products (see section 3.4).

In 2024, this work will continue with the implementation of a detailed carbon trajectory, supported by Carbone 4. This will focus more closely on raw materials and freight. The aim is to continue to develop the company, which carries out an activity that is essential to human health, while reducing its carbon intensity.

INDICATORS

1- Carbon footprint 2023

	Tons of CO2 equivalent
Scope 1 - Gross GHG emissions	2040
Scope 2 - Gross GHG emissions (location-based)	5050
Scope 3 - Gross GHG emissions	40960
Total GHG emissions	48050
GHG emissions intensity, location-based (total GHG emissions per net revenue)	282,5

	Millions of euros
Net revenue	170,1
Net income used to calculate GHG intensity	170,1



Breakdown of emission sources 2023



2- Emissions reduction*

	Reduction in GHG emissions (in tonnes of CO2 equivalent)	Reduction in GHG emissions (%)	Change in carbon intensity (in metric tons of CO2 equivalent/ million euros of sales)
Scope 1	-970	-32,2	-6,5
Scope 2	-570	-10,1	-4,9
Scope 3	+640	+1,6	-7
Total	-900	-1,9	-18,4

*With 2021 as reference year



(Carbon intensity per million euros of turnover)

The company has thus **reduced its carbon intensity by 6.1%** compared with its reference year (2021). This is due in particular to **reduced energy consumption** at industrial sites which was achieved despite an increase in volumes produced and marketed.

2 - Energy management

Since 2022, the company launched a **3-year plan to reduce energy consumption**, following an **energy audit** of its production sites in 2021.

This 1st plan consists of:

- Recovering energy from existing production facilities and utilities;
- Implementing control systems to optimize the operation and efficiency of heating and combustion systems;
- Replacing certain equipment with less energy-intensive equipment;
- Changing the technology of lighting systems;
- Studying the feasibility of installing photovoltaic panels on production sites;
- Adapting air-conditioning systems to production activities;
- Renovating and insulating certain buildings and production areas;
- Measuring energy consumption points.

This action plan, steered by the CSR Director, is carried out in collaboration with the utilities, general services, plant managers and industrial management teams.

Thanks to this energy reduction plan, the company estimates that it could achieve a **15% reduction in energy consumption** over 3 years, on a like-for-like basis.

In 2023, **90%** of the actions planned at the various sites **have been implemented**, and their effects will be measured in 2024. Further actions to reduce consumption and produce renewable energy will continue in 2024.

In addition to this 3-year sobriety plan, the company is studying other actions to be deployed in the future, in order to contribute to its **2030 carbon trajectory**.

INDICATORS

Consumption in 2023 :

	MWh
Total energy consumption (electricity) related to company operations	19776
Total gas consumption	9339
Total energy consumption from renewable sources	0
Percentage of renewable sources in total energy consumption	0
Renewable energy* production	65

*Source of the photovoltaic panels installed on the Polish site

3 - Travel policy

Although travel is not the most significant factor in the company's carbon footprint, it has nonetheless seized the challenge by introducing consistent practices to ultimately minimize its impact on the environment, control its environmental and financial costs and disseminate a culture of best practice.

To this end, our travel policy has been reviewed. The first recommendation is to **avoid physical travel** by making maximum use of audio, video and web-conferencing tools, and to travel only when **demonstrably necessary**.

In addition, modes of transport with the lowest impact, such as the train, but also economy class travel, which has a smaller footprint than travel categorized in higher classes, are strongly encouraged.

With this in mind, the rules are defined as follows:

For air travel:

Domestic flights: Train is still the strongly recommended option. Flying is still possible:

- if the train journey takes more than 5 hours;
- if flying is the only option;
- for extreme emergencies and with the approval of the immediate superior.

International flights: class of carriage is determined as follows:

- Short-haul: (0 to 6 hrs): economy class;
- Medium-haul: (6 to 10 hrs): premium class is authorized;
- Long-haul: (> to 10 hrs): premium class must be considered, otherwise business class is authorized.

Train travel:

We strongly recommend train travel.

Finally, a new booking platform has been deployed, to standardize the process and optimize **data collection**. Thanks to this new tool, the company can monitor the carbon footprint of employee travel in real time.

#3.2

Fight against pollution

ESRS
= E2

- Pollution of air, water, soil, living organisms and food resources

CONTEXT AND ISSUES

Whether the risk is to the air or to terrestrial or aquatic ecosystems, **controlling environmental impacts** is at the heart of every industrial process. Macopharma has put in place appropriate policies and measures for activities generating these risks, at each site level.

In particular, bag **manufacturing processes** require the use and handling of plastic raw materials and chemicals. However, the plastics used are in solid form (film reels, granules and powders), generating **limited and controlled pollution risks**. In addition, all processes take place indoors, and chemicals are stored under containment. Atmospheric emissions come mainly from natural gas combustion units, and other emissions are **treated beforehand**.

The production of single-use plastic medical devices generates waste during manufacture and at the end of their life. Plastic waste is a major cause of pollution worldwide, and has a particular impact on biodiversity. Although the use of single-use medical devices in the transfusion chain is highly regulated, the Group is making efforts to **limit their impact**. All these measures are described in section 3.4 - Circular economy and waste management.

POLICY AND ACTION PLAN

Throughout its production process, Macopharma is careful to ensure the safety of its processes in order to **minimize the impact of its activities on air, water, soil and biodiversity**. This is illustrated by **regular analysis of industrial risks**, monitoring of water discharges and compliance with <0.1% thresholds, with all 3 production sites connected to local wastewater treatment plants. In addition, **the ISO 14001-certified environmental management system** ensures continuous improvement in the control of environmental impacts.

INDICATORS AND RESULTS

Atmospheric emissions, which are mainly due to combustion activities using natural gas (heating and production processes), are included in the carbon footprint (scope 1). Between 2022 and 2023, the company has noted a **15% reduction** in natural gas consumption in CO2 equivalent.

With regard to indirect atmospheric emissions from chillers, in 2023 the company recorded minor fugitive losses of 53kg of R407C, 63kg of R410A and 45kg of R134 for all its production sites. These losses are then included in the company's carbon footprint.

- Substances of concern, of very high concern, microplastics

CONTEXT AND CHALLENGES

The materials used by Macopharma are mainly plastics such as PVC, polypropylene and polycarbonate. These materials are produced and distributed by large specialized companies. Macopharma generally has no influence on the production of these materials. Nevertheless, **the Group pays constant attention** to the use of substances defined as being of concern or very high concern by REACH regulations, and seeks to minimize their impact.

The elimination of substances of high and very high concern, as well as microplastics, from Macopharma's products is a specific and ongoing focus of attention, at the heart of its business model. Through its role in the transfusion chain, the Group has always been committed to **protecting the health of users**. In this way, it contributes to public policies aimed at eliminating the most toxic chemical substances for people and the environment, notably DEHP (see section 4.3.1 S4 - Consumers and end-users - Health and safety). The increasing complexity and rapid evolution of regulations in this area call for considerable expertise. The challenge is also to respond to changing calls for tender and societal expectations. A large part of Macopharma's R&D efforts is dedicated to the search for **alternative solutions**. Risk is controlled upstream by **monitoring regulations** to identify substances that could one day be subject to restrictions, and thus anticipate their substitution. The risk is also controlled by constant, regulated monitoring of the presence of microplastics in blood bags.

POLICY

Macopharma is committed to **respecting and anticipating regulations** concerning the management of substances of concern and microplastics in its products, which can have an impact on the environment and the health of its users. This is reflected in the monitoring and implementation of REACH regulations, assiduous regulatory watch and strong investment in research and development. Macopharma ensures that the composition of its products meets the requirements of current European regulations (see section 4.3.1).

Objective:
100% of customers converted to DEHP-free products by 2028

#3.3

Water and marine resources

ESRS
= E3

CONTEXT AND ISSUES

The water used in Macopharma processes is drinking water. This water is pre-treated (softened, osmosed and distilled). It is used in the preparation of anti-coagulant and preservative solutions, and for steam production to sterilize finished products and process equipment. However, **water consumption remains moderate**. Macopharma's sites are not located in areas subject to water stress, with the exception of the Tunisian site. Water consumption represents a **small amount of purchases**, so an increase in the price of water would have a moderate financial impact at Group level. Nevertheless, the Group remains vigilant about its water supplies, as global warming could lead to administrative restrictions and, in extreme cases, disruptions to production. The "essential" nature of the Group's products significantly reduces this risk.

POLICY AND ACTION PLANS

The risk posed by the **water supply** to the company's activities is taken into account in **business continuity** risk analyses. In this context, access to water is monitored at all sites. In view of the need to **adapt to ongoing climate change**, the company is studying operational solutions to **reduce the quantities of drinking water consumed** (installation of pressure reducers, leakage control, etc.) and to change usage principles (such as the addition of a water storage tank in Tunisia, to compensate for the water cuts that can occur in the region during difficult climatic conditions).

A study is also underway at the Tunisian site to **collect and store rainwater** for use in the upkeep of green spaces and some outdoor cleaning operations.

INDICATORS

Consumption for 2023 :

	water cubic meters
Total water consumption	50412 m ³
Total water consumed in high water risk areas	24462 m ³
Water consumption intensity per million euros of sales	296.4 m ³ /M€ of turnover

Reference income: 170.1 million euros

#3.4

Circular economy and waste management



CONTEXT AND ISSUES

The transfusion chain uses **single-use** plastic medical devices (transfusion kits). They play an essential role in health protection, **guaranteeing the integrity of the products collected**. However, at the end of their life cycle, as they are classified as biological waste with infectious risks, they generate large volumes of plastic waste, as well as used needles whose end-of-life is highly regulated. The processes involved (notably the separation of blood compounds and their preservation) leave little scope for substituting plastic with another container.

As this is a **highly regulated activity**, the use of recycled plastic in the manufacture of products is complex, and could only be applied to certain components that have no contact with blood during use.

Used transfusion kits become infectious waste, which **must be incinerated or decontaminated before being crushed** and landfilled. In this sense, the company's room for maneuver lies in its **management of the plastic waste generated during the kit manufacturing process**. In addition, a small proportion of Macopharma's waste falls within the scope of the WEEE directive (Waste Electrical and Electronic Equipment), essentially waste from **industrial processes and from equipment** put on the market (after-sales and end-of-life). The industrial risk concerns the monitoring and anticipation of regulations on the nature of the materials used, and the possible rise in the price of plastics, which is highly correlated with the price of hydrocarbons.

The search for recycling solutions for end-of-life kits would enable Macopharma to distinguish itself commercially, in a business that is still immature and sensitive on the subject. Solutions require constant innovation.

POLICY

Macopharma is committed to **optimizing the use of resources and waste management**. The **EMS (Environmental Management System)** covering all its plants already includes a detailed waste management policy, but the company wishes to go further by setting itself the target of reducing its industrial waste by 30% by 2030, on a like-for-like basis.

Target of 30% reduction in industrial waste between 2022 and 2030
Target of 100% of products covered by a life-cycle analysis

The current waste sorting process has been in place since 2010, with the following classification by 2023:

PVC from our various workshops (cutting, packaging, etc.) is recovered for recycling or as a secondary raw material for manufacturing PVC materials (at all 3 sites).

Polyethylene and filter media are recovered as secondary raw materials, after granulation, for recycling (French plant).

Flexible plastics, from raw materials packaging (RM), primary packaging losses from kits or other parcel packaging, are recovered as a secondary raw material for recycling (on all 3 sites).

Flexible paper and cardboard, from RM or other parcel packaging, is recovered as a raw material for recycling (on all 3 sites).

Non-hazardous industrial waste, similar to household and final waste, is recovered by incineration with energy recovery (French site), incinerated (Polish site) or landfilled (Tunisian site).

Infectious waste: are recovered by incineration with energy recovery (French site), incinerated (Polish site) or landfilled after detoxification and shredding (Tunisian site).

SIW (Special Industrial Waste) is :

- Recovered by incineration with energy recovery and physico-chemical treatment for the French site :
- Recovered by incineration, detoxification and physico-chemical treatment for the Polish site;
- Recovered by incineration, detoxification and physico-chemical treatment in specialized facilities in France, for the Tunisian site.

Finally, **WEEE** (Waste Electrical and Electronic Equipment) - batteries, lamps, printed circuit boards, electronic components - are recovered through reuse or recycling at the French and Polish sites.

ACTION PLANS

1 - Partnerships to reduce industrial waste

Since 2022, Macopharma has been working in partnership with one of its PVC suppliers, Renolit, to reduce their respective environmental impacts.

Several actions were undertaken in 2023:

Return of raw material packaging: For the French site, the improvement in the volume of returns to suppliers of packaging for PVC reels and other components continued. This action has also been studied for the Polish and Tunisian sites. For the Tunisian site, this action was not deemed feasible in view of the environmental and financial impacts generated. However, the packaging return process was implemented at the end of the year for the Polish site.

Optimization of PVC reel size: Given the PVC film losses generated by frequent reel changes during the production process, the switch from 300m to 725m reels more than halved the associated losses. The use of 725m PVC coils is already in use at the French site for the pouch production machines in the welding workshop. This change has been studied for the welding workshop at the Polish site, requiring adaptations to handling operations and delivery practices, and has been in effect since the beginning of 2024.

Recycling PVC film waste from our machine cutting of our bags: As mentioned above, PVC film waste is currently recycled by specialized companies as a secondary raw material for the manufacture of various materials and equipment. Macopharma's ambition, with its partner Renolit, is to be able to recover this material and re-inject it into the production process.

2 - Product lifecycle analysis

In order to optimize its use of resources and waste management, and potentially reduce its carbon footprint, Macopharma aims to cover 100% of its product range with an LCA (Life Cycle Assessment) by 2030.

This approach was initiated in 2023. For this first exercise, the company has chosen to target two products: a blood transfusion kit and an illumination machine with its associated bag. This kit represents 20% of the production of blood bag range. To carry out this exercise, the company is accompanied by Bureau Veritas. The working group was able to organize an initial workshop, structure data collection and map data for the blood transfusion kit.

Once all this data has been collected (scheduled for 2024), Bureau Veritas will analyze it and draw up an LCA report. This will enable us to analyze the main environmental impacts of the products and thus identify eco-design opportunities.

Eco-design projects

The company places innovation at the heart of its business model (see section 4.2.1), as it can be an opportunity to respond to environmental issues. For example, a project to reduce the mass of some of its components would reduce the quantity of waste and the environmental impact generated by its products, both during the manufacturing process and at the end of their life.

3 - Supporting healthcare professionals in the responsible management of end-of-life kits

As previously stated, used kits must be incinerated or autoclaved before shredding. The instructions for use (for MDR kits) have been revised in the form of logos: they inform healthcare professionals that an unused kit, and any part of the single-use equipment, can be separated and sent for recycling. It also specifies what is to become of the various elements of the kit (to be disposed of, recycled or treated according to the procedure for biohazardous waste).

INDICATORS

Composition of products sold (transfusion kit):

Rate of recyclable content in products	0%*
Rate of recyclable content in product packaging	100%**

*if used

** if recycling channel exists in country of use

Waste generated in 2023:

	2023
Total waste generated	1 596,29 tons
Non-recycled waste	340,79 tons
Percentage of waste not recycled	21,35%
Total hazardous waste	47,98 tons
Total radioactive waste	0 tons

Hazardous waste:

Hazardous waste directed to disposal in tons	47,98
Hazardous waste directed to disposal by incineration	46,59
Hazardous waste directed to disposal by landfilling	0
Hazardous waste directed to disposal by other disposal operations	1,39
Hazardous waste diverted from disposal	0
Hazardous waste diverted from disposal due to preparation for reuse	0
Hazardous waste diverted from disposal due to recycling	0
Hazardous waste diverted from disposal due to other recovery operations	0

Non-hazardous waste (PVC, paper, cardboard, etc.):

	2023
Total non-hazardous waste diverted from disposal in tons	1 255,5
Non-hazardous waste diverted from disposal due to preparation for reuse	0
Non-hazardous waste diverted from disposal due to recycling	1 255,5
Non-hazardous waste diverted from disposal due to other recovery operations	0
Total non-hazardous waste directed to disposal	292,81
Non-hazardous waste directed to disposal by incineration	232,31
Non-hazardous waste directed to disposal by landfilling	60,5
Total non-hazardous waste	1 548,31

#4

SOCIAL AND SOCIETAL INFORMATION

#4.1

Our employees

◦ Organization/governance

Social issues are **the responsibility of the Director of Human Resources and Sustainable Transformation (HRD), a member of the Executive Committee.**

Each production plant has a **local team** responsible for managing human resources (HR) policy and social issues. Subsidiaries and Corporate teams are served by an HR team based at Group headquarters.

The company has a number of tools at its managers' disposal, notably digital ones, to ensure the reliability and standardization of processes. For example, each manager has access to HR software for monitoring leave, annual interviews, annual training assessments, potential assessments, talent reviews and salary reviews.

◦ HR policies

HR policy is structured around 4 points, managed at corporate level:

- salary policy, which organizes compensation and benefits (see section 4.1.8);
- recruitment policy (see section 4.1.6);
- skills development policy (see section 4.1.3);
- and occupational health and safety policy (see section 4.1.4).

◦ Engagement

In order to assess the commitment of its employees, Macopharma has renewed its **"Your Voice"** survey in 2023 (after the first edition in 2020).


Addressed to **all Group employees**, in 5 languages, this barometer gave employees a voice, anonymously, through **10 key themes**, grouped into 49 questions (open-ended or to be evaluated): management, company strategy, work environment, sense of belonging, skills, team spirit, trust, career prospects, well-being at work and recognition.

INDICATORS

Participation

Total	
Participation rates	1652 answers
Net participation rate	83%
Distribution of respondents	
Graded employees	20%
Employees & technicians	15%
Workers	65%

Global result :

SCORE
ENGAGEMENT

This questionnaire helped to unite teams, identify Macopharma's strengths and areas for improvement, and guide the company in monitoring and steering its action plans.

Following this survey, the teams suggested concrete actions that could be taken at local level or across the Group:

- 160 concrete levers identified at local level
- 40 initiatives to be deployed at Group level

This approach is part of a commitment to listening to Macopharma teams, which translates into: continuous interaction with employees, the development of a feedback culture, recognition, but also empowerment of everyone in the face of these challenges.

#4.1.1


Overview of our employees

Distribution in countries with 50 or more employees:

	FRANCE	POLAND	TUNISIA	TOTAL
Number of employees (Head count/FTE)	750	543	733	2026
Permanent employees	618	371	457	1446
Temporary employees	132	172	276	580
Employees on non-guaranteed hours				0
Full-time employees	717	543	733	1993
Part-time employees	33	0	0	33

Breakdown by gender:

	WOMEN	MEN	TOTAL
Number of employees (Head count/FTE)	1631	395	2026
Permanent employees	1139	307	1446
Temporary employees	492	88	580
Employees on non-guaranteed hours			0
Full-time employees	1603	390	1993



#4.1.2

Social dialogue and collective bargaining

ESRS
= S1

CONTEXT AND CHALLENGES

Macopharma strives **to maintain a constructive social dialogue** with all its social partners, at both plant and corporate level. This organization enables employee representatives to negotiate, consult each other and management on social and company issues.

POLICIES

Social dialogue

Macopharma has a **policy of social dialogue at all its production sites**. This is structured in France, Tunisia and Poland, in accordance with **national legislation**. Depending on the country, issues such as wages, social protection, safety, working conditions and the negotiation of new agreements are discussed with the social partners. **Wage negotiations** are held annually at each site.

Expression meetings are also organized, so that employees can pass on information or questions to management.

Social works

Each site is also involved in social works, through which a continuum of actions is implemented each year, and has a dedicated budget. Management is committed to ensuring that each site has a budget enabling it to develop **access to sport and culture**, and to provide **economic support** in certain situations.

INDICATORS

	Collective Bargaining Corevage		Social dialogue
	Employees - EEA (for countries with > 50 empl. representing > 10% total empl.)	Employees - Non-EEA (estimate for regions with > 50 empl. Representing > 10% total empl)	Workplace representation (EEA only) (for countries with > 50 empl. Representing > 10% empl)
Coverage rate			
80-100%	France/Poland	Tunisia	France/Poland/Tunisia

#4.1.3

Training and professional development

ESRS
= S2

CONTEXT AND ISSUES

Expanding internationally and with the need to **master skills**, Macopharma is committed to offering its employees the opportunity to grow and prepare for the future. This commitment is reflected in an ambitious **skills development plan**. Continuous skills acquisition is an asset for developing employees' **autonomy, employability and quality of life at work**. Learning is at the heart of the employee experience. It enables us to support career paths and respond to individual development aspirations. Skills development also helps to ensure the company's performance by nurturing its **#engagedForLearning** pillar, and to adapt to a changing world and evolving professions.

Finally, at Macopharma, training and career development are key retention issues. Investing in employee development helps to ensure that resources are well matched to the Group's needs, in a job market that is under pressure for certain specific positions.

[Reminder 2030 Ambition]

Objective is an internal mobility greater than 25 %

POLICY

Macopharma bases its skills development policy on the 70-20-10 model, linking 3 inseparable aspects of learning:

- Experiential (70%): learning by doing
- Social learning (20%): learning from peers
- Training (10%)

The **skills development plan** is deployed throughout the year and enriched by "**HR Timing**" highlights. Between January and April, several tools and processes are deployed to **monitor, evaluate and feed employee development**.

The calendar opens with **Annual Reviews** (Annual Business Reviews [ABR] and Professional interviews [PI]) and **Potential Assessments**. These are followed by the Talent Review exercise. Lastly, two campaigns - respectively 1) to evaluate last year's Objectives and associated Bonuses, and 2) to set Objectives and Bonuses for the current year - complete the annual performance cycle.

The annual review (AR), between the employee and his/her manager, enables :

- A qualitative assessment of the year as a whole; and for the employee, feedback from his or her manager on the way he or she has performed in the job;
- An assessment of the associated business skills and behavioral competencies (or of the Leadership Model culture for executives);
- In the PI section, a definition of the employee's development priorities and training needs.

This interview can be quarterly for certain functions and countries: Production in Tunisia and Poland, for example, which makes it possible to smooth out monitoring on a more regular and operational basis.

The Annual Review is also an opportunity to revise the employee's mission statement, if necessary.

The evaluation of potential (and performance) is carried out by the manager via a dedicated process and form, for all Group managers, in addition to the Annual Interview, with a view to Talent Reviews.

Finally, the **Talent Review** is a non-mandatory annual exercise during which all potential assessments are adjusted and calibrated by management and the HR team. Feedback from the Talent Review assessments and associated arguments are then shared by the manager with his or her teams.

ACTION PLANS

In addition to assessing individual needs, each year the company defines strategic priorities which are then translated into targeted or collective development plans. These can be illustrated through actions to promote experiential learning, training or social learning.

◦ Experiential learning

In order to encourage experiential learning, which accounts for 70% of learning dynamics according to Macopharma's policy, the company is implementing several actions.

A communication campaign is launched at the start of each HR Timing program to **raise managers' awareness** of the different learning models and the different sources of employee development. The campaign emphasizes the importance for managers of proposing enriching assignments and situations in which their teams can experiment and learn by doing.

Thanks to the Talent Review exercise, the company works to identify and support the **development of potential employees**, with targeted actions and customized development plans to help them progress and/or enhance their potential (for example, recruiting and managing a work-study student). This exercise also enables the company to work on succession plans, as well as on training programs for talent/potential and experts (high performers).

◦ Social learning

Social learning consists of interactive learning, by peers and thanks to all the parties involved, we speak of **mentoring, feedback, networking or transmission by peers**.

Examples include the **"digital workplace"** program, through which "digital ambassadors" (identified among employees) disseminate culture and best practices on Microsoft 365 tools; or the **"skills transmission"** program, which enables production operators to progress to the position of line conductor, through a customized training program. This transfer of skills will enable a dynamic sharing, safeguarding and learning process on the job. It takes the form of pedagogical interaction between a "knower" (in-house staff: technical expert, process and improvement engineers, maintenance technician, machine operator, project/methods engineer) and several learners, resulting in the acquisition of skills and the emergence of new work practices.

→ 10 digital ambassadors

→ 400 employees sensitized to better use of digital tools

Training

Macopharma's training policy comprises **three phases**: initial staff training, on-the-job training and ongoing training. Training can take the form of face-to-face, e-learning or hybrid training. Training courses are developed, monitored and managed by the HR department, in collaboration with the department concerned when a specific field is involved (quality, HSE, etc.), or with managers.

The training policy has a number of objectives:

- To enable all employees to familiarize themselves with the standards they need to follow in the course of their work;
- To consolidate individual and collective performance in the workplace (short term);
- To facilitate and support the company's development (medium and long term);
- To assist and support the company's Human Resources.

These objectives are reflected in a new employee **welcome program**, and annually in training initiatives included in a skills development plan, which serves as the basis for implementing annual orientations.

A. Initial training

To ensure that all employees have a **common grounding**, each newcomer is given a day's "induction training", which is compulsory for access to the workstation.

This training includes at least :

- General information on the company;
- Information on the products manufactured;
- Quality training (Good Manufacturing Practices - GMP) with assessment;
- "Health Safety Environment" (HSE) training with assessment and distribution of a booklet covering safety and environmental rules (led by the HSE department), as well as a section on the Business Continuity Plan (BCP);
- A site visit.

At the same time, a "DM (Medical Devices) Culture" training course, with assessment, is carried out via e-learning for those with access to the platform, or face-to-face for others.

Finally, for new employees with access to the e-learning platform, modules are developed according to their position and the needs identified in advance by the manager.

B. On-the-job training

For all new employees, a specific **induction program** (adapted to the employee's mission) can be set up by his or her manager.

If the position is subject to a Significant Environmental Aspect (SEA), then training is provided on the operational control of this aspect. If the position is not subject to an SEA, awareness-raising is provided on the importance of compliance with environmental policy, the site's main SEAs, the actual or potential environmental impacts of the site's activities, the role of each employee in the Environmental Management System (EMS), and the consequences of any deviations from established procedures.

TOP 5 OF MOST ATTENDED TRAININGS:



Security



CSR



Quality &
Regulatory



Management



Personal
development

C. Ongoing training

Finally, training continues throughout an employee's career. This involves training courses set up according to the skills development plan, the specific needs of the employee (at his/her request or identified by his/her manager) or the company's strategic orientations. These training courses can take a variety of formats: face-to-face, distance or e-learning, run in-house or by external trainers, synchronously or asynchronously. Hybrid formats have also become increasingly popular, as they are more flexible and agile.

Examples of continuing training courses:

→ Product quality training:

All personnel required to enter production and storage areas or control laboratories, as well as any other person whose activities could present an influence on product quality, must receive repeated training on the concepts of quality and good manufacturing practices, as well as specific requirements for product manufacture. This training must be renewed annually (campaign training).

→ Self-access training:

In parallel with the actions set out above, Macopharma is pursuing its commitment to ongoing proactive training: through the use of the Grow@Maco self-directed personal development platform (via partner Edflex), on which employees access self-access content, in a variety of formats (MOOCs, articles, podcasts, etc.) and on a variety of subjects (management, CSR, project management, excel, etc.).

INDICATORS

Average number of training hours per person, by gender	Men	Women
Graded employees	23,1 hours	26,3 hours
Employees & technicians	19,4 hours	10,2 hours
Workers	4,8 hours	3,2 hours

(Calculation method: number of consolidated hours / number of people in each gender category).

% of employees who have completed at least one follow-up interview	Men	Women
Graded employees	98%	96%
Employees & technicians	83%	92%
Workers	98%	93%

(Calculated according to the actual validation of the workflow (Manager validation) for the 2023 annual performance reviews for the following scopes: Graded employees, employees and technicians (Group) and Workers (France). The performance review for workers (CSP) in Poland and Tunisia is carried out according to a different process with variable recurrence, this indicator is not available for this scope in 2023).

→ Internal mobility rate⁴: **38%**

[Reminder ambition 2030]

Maintain an internal mobility rate of 25%.

⁴ Functional mobility excluding workers. Ratio of total positions taken by internal employees versus total open positions.

#4.1.4

Health and safety

ESRS
= S1

CONTEXT AND CHALLENGES

Ensuring a **safe and healthy working environment** for its employees is one of Macopharma's ongoing concerns and responsibilities, whether in terms of **physical or mental health risks, workplace safety** or **personal data security**. On our production sites, physical risks are concentrated on jobs involving repetitive movements, which require the prevention of musculoskeletal disorders (MSD).

Other occupational exposures are related to the use of machines, equipment, chemicals, biological products, risks associated with the pace of work, etc.

These exposures are assessed, and the ratings are included in the **company's single documents**. The associated action plans are included by type of exposure in the **HSE progress plans**, in order to reduce the impact on health.

Compliance with the most stringent **health and safety standards guides** the organization of HSE teams in order to reduce accidentology and related absenteeism. These standards include a broad prevention component, and follow a **continuous improvement approach**, particularly in countries where regulations are less stringent.

Finally, with regard to **personal data management**, the Group's business does not involve the processing of patient data. It is therefore not a specific issue. However, Macopharma is concerned by the societal issue of personal data protection and cybersecurity, as is any company.

— HSE (Health, Safety, Environment)

POLICY

In its day-to-day operations, Macopharma is committed not only to complying with the applicable HSE regulations to which it is subject, but also to **going beyond its legal and regulatory obligations** to constantly improve and become a benchmark in this field.

Macopharma's commitments to employee health and safety are set out in its **HSE policy** (see appendix B).

All Macopharma sites are **certified** and follow an occupational **health and safety management system** in compliance with **ISO 45001**.

ACTION PLANS

a) Prevention campaigns Training

- Face-to-face HSE training for new recruits, training and regulatory approvals (forklift driving, electrical approvals, autoclave operation, etc.), e-learning materials.
- HSE "job-specific" training: on the control of chemical risks (ACD and CMR), biological risks, HF risks, electrical risks, risks associated with working at height, etc.
- Safety flash: dissemination of information on accidental events, if possible, as soon as they occur at other sites.
- Safety challenges with prizes: a challenge is organized each year between the various departments to reward good behavior and those who have achieved 0 work-related accidents.

- The company is also working on the behavioral factor, which is often the cause of accidents, in order to prevent inappropriate behavior in relation to safety instructions. These behavioral aspects are assessed with staff during scheduled inspections and all field data.
- Establishment of a process for declaring near-accident situations, accessible to all, in order to act as early as possible on risky situations to avoid accidents

b) Work on ergonomics

In order to reduce the risk of MSD on workstations subject to repetitive movements, **post rotations** have been set up, in workshops allowing such logistics, for our 3 plants.

In France, an **ergonomic study** was carried out by the Occupational Health Department, followed by an **action plan** which was defined at the end of 2021, with deployment scheduled between 2022 and 2024. The action plan, containing several projects such as ergonomic layout of workstations, handling aids, review of processes and training of engineering teams in ergonomics.

c) Workstations

In order to **anticipate potential safety risks**, a risk sheet is drawn up for each workstation, enabling each employee to be trained in the risks intrinsic to his or her position and, above all, to communicate good prevention practices.

Workstations have collective prevention and protection means. 100% of equipment and machines are **inspected by an approved body to ensure full compliance** before being made available to our employees. These checks are also repeated whenever any modification or work is carried out on safety loops. Technical teams regularly test these safety devices as part of preventive plans.

d) Audits

Internal behavioral audits planned or unannounced visits, and discussions with operators are organized to check that knowledge of general safety instructions specific to the position is maintained, and to identify any need for additional training or equipment.

e) Communication with teams

In order to **encourage exchanges with teams**, and facilitate the flow of information, regular meetings are organized in all plants. Team meetings are held every day before the start of each shift. A process of “tier meetings” has been set up as follows:

- Tier 1: Operator feedback on equipment, safety, quality and deadlines.
- Tier 2: information that goes up to team level.
- Tier 3: information that goes up to the plant management committee.
- Tier 4: information that goes up to the corporate organization (potential inter-site impact). These take place 3 times a week.

INDICATORS

	2023
Percentage of people in its own workforce who are covered by health and safety management system based on legal requirements and (or) recognised standards or guidelines. Whole group scope.	100
Number of fatalities in own workforce as result of work-related injuries and work-related ill health. Whole group scope.	0
Number of fatalities as result of work-related injuries and work-related ill health of other workers working on undertaking's sites	0
Number of recordable work-related accidents for own workforce	12
Rate of recordable work-related accidents for own workforce	3,53
Number of cases of recordable work-related ill health of employees	6
Number of days lost to work-related injuries and fatalities from work-related accidents, work-related ill health and fatalities from ill health related to employees	4821
Percentage of own workforce who are covered by health and safety management system based on legal requirements and (or) recognised standards or guidelines and which has been internally audited and (or) audited or certified by external party	100

*Occupational diseases recognized by the social security system at the time of writing

** Of which 647 for accidents at work and 4174 for occupational diseases. This includes declarations from previous years still having an impact in 2023.

Personal data protection

The Group complies with the obligations set by the **General Data Protection Regulation (GDPR)**, guaranteeing the protection of the data of its employees, customers or partners.

To achieve this, the system includes a **DPO (Data Privacy Officer)**, ensuring **compliance with all GDPR obligations** as well as **system security**, and a **compliance program**.

The compliance program, audited in 2022, is applied throughout the Group's perimeter and thus goes beyond simple regulatory compliance. It is based on the "privacy by design" model and includes :

- A charter for the use of tools signed by all employees;
- Reviewing and updating the register of processing activities;
- Mapping personal data flows;
- Performing impact analyses on processing operations that have had changes in scope;
- Training and raising employee awareness of the GDPR.

INDICATORS

→ 448 people trained about GDPR between 2021 and 2023

#4.1.5

Quality of life at work

ESRS
= S1

CONTEXT AND ISSUES

Quality of life at work is a set of factors whose perception largely depends on the profile of employees. Depending on their age, family situation, ambitions and working environment, they have different expectations in terms of working hours, flexibility and the possibility of teleworking, for example.

A deterioration in working conditions could have repercussions on the attractiveness of the company and increase absenteeism. In Macopharma's case, the requirement for continuity of operations means precise operating procedures and reduced flexibility for production jobs, which account for 80% of the workforce.

Conversely, a work-life balance policy promotes **well-being at work**.

The subject of work-life balance is also addressed during annual performance reviews (see section 4.1.3).

ACTION PLANS

1 - Organization of telecommuting for tertiary positions

In line with contemporary changes in working patterns, Macopharma has been offering its employees the possibility of teleworking since 2020 (2022 for Tunisia and 2023 for Poland). This applies to employees on permanent contracts, whether full-time or part-time, with a length of service in the company equal to or greater than the trial period. Full-time employees have 2 days' teleworking per week, part-time employees 1 day. In the case of subsidiaries, these are mainly sales positions.

2 – Supporting parents

Macopharma invests 70,000 euros a year and partners with childcare facilities to reserve places for employees at its French sites who need childcare.

Family-related leave, the company is careful to comply with the legal requirements of each country.

INDICATORS

100% of employees are allowed to have family-related leave

Percentage of employees entitled to take family-related leave
Percentage of entitled employees that took family-related leave
Percentage of entitled employees that took family-related leave by gender [table]

#4.1.6

Equity, equal opportunity, inclusion

ESRS
= S2

CONTEXT AND ISSUES

In its ambition to 2030, Macopharma is committed to **ensuring a fair and inclusive working environment** for its employees. This means creating an environment in which everyone **benefits from the same treatment and opportunities**, in an equitable manner, regardless of gender, age, disability, ethnic or social origins, career path, etc. The company believes in diversity to enrich its ways of working, stimulate collaboration and carry its **#OneMaco** value.

Historically, Macopharma has been working for many years on its policy of employing **people with disabilities**, enabling it to make progress in this area every year and to be recognized by its local partners. Access to employment and job retention for people with disabilities are very important factors for autonomy and social inclusion.

2030 Objective : Gender equality in top management positions

POLICY

Macopharma's diversity and inclusion policy is characterized by a determination to ensure that all employees and candidates benefit from the same opportunities in an equitable manner. This commitment is embodied in the company's **"Ethics Charter and Code of Conduct"**.

Macopharma is proud of its employees, their expertise, their daily involvement and their diversity.

It is thanks to this diversity of talents, energies, cultures and knowledge that Macopharma has evolved over the years and is able to strengthen its identity, innovation, image and competitiveness. This is why Macopharma is committed to :

- Valuing and developing the motivation and performance of its employees;
- Promoting the exchange and creation of new ideas;
- Creating a spirit of initiative;
- Developing communication and transparency.

Various measures are taken to guarantee the professional development of each and every employee in a fair and equitable manner with regard to, for example:

- Professional equity between men and women;
- Work-life balance;
- Employability of people with disabilities.

Our corporate culture is designed to give everyone a chance:

- During the recruitment process;
- For access to trainings;
- In the internal mobility process.

ACTION PLANS

1 - Promoting gender equity and parity

Macopharma has deployed a business-specific reference system to allocate salaries for new hires and promotions according to objective criteria, taking into account the position and local conditions. The monitoring of pay equity criteria, such as the individual social report or the professional equality index in France, enables any anomalies to be identified.

In 2023, the company also wished to go beyond its legal obligations by launching the monitoring of pay equity, for equal skills, at Group level with **the implementation of this index within its other sites**, starting with Poland and with the aim of extending it geographically in the future.

2 - Employment and integration of people with disabilities

For some 13 years now, Macopharma has been developing an active disability policy to recruit, retain and raise awareness among all staff. This policy has enabled us to increase the proportion of people with any type of disability from 3.8% in 2008 to 7.8% in 2023. The efforts made to enable them to carry out their jobs are illustrated by the fact that 30% of positions have been adapted.

This policy is illustrated in particular by the active work of a disability officer for the French sites.

3 - Raising awareness

After more than 10 years of organizing a week-long event to promote the employment of people with disabilities, in 2023 Macopharma has decided to extend awareness-raising to the following theme: intergenerational issues, racism, gender, culture, gender equality and sexual orientation.

In November, for the first time, we organized the **“Week of Living Together”**, with several activities taking place throughout the week, both face-to-face and digitally, in order to reach the entire group.

First, activities crossing several themes for the whole group: quiz, online game, targeted communications and digital 3D exhibition.

Among the targeted actions :

- On disability, a focus on invisible disability with diabetes awareness and various communication actions. The traditional “handicafé” and sale of brioches in aid of the *Papillons Blancs* association on the French site. We also visited two associations in Tunisia.
- Various games and workshops on: the cultural diversity that makes up our teams; gender equality, with a focus on a woman’s professional career; and intergenerational skills, exploring the complementarity of junior and senior skill.

4 - Develop recruitment based on potential, personality and soft skills

Faced with the competitive challenges of recruiting and retaining talent, in order to limit the cognitive biases that can be present during a recruitment process, and with the aim of identifying behavioral information independent of the CV, Macopharma launched a new tool in 2022 with partner AssessFirst. Deployed for all technicians, employees and graded employees recruitment in France and in our sales subsidiaries, it consists of an asynchronous phase of 3 online personality tests: Behavior - Motivation - Reasoning; These tests are carried out on internal and external candidates. They complement and improve the recruitment process by assessing the candidate's potential and behavioural skills.

5 - Working with vulnerable populations


Since 2022, Macopharma has been committed, particularly at its French site, to helping people who are far from employment, find their way back into the world of work. In partnership with Eurasanté, a training, integration and return-to-work pathway has been set up, accessible to all types of jobseekers, young graduates with diplomas, as well as employees coming from Plan for safeguarding employment (PSE) or undergoing retraining.

INDICATORS

M/F equality index France & Poland → **89% and 66%**
(Index defined by French law : [https:// travail-emploi.gouv.fr](https://travail-emploi.gouv.fr))

% of employees with disabilities in France → **7.8%**

OETH (employment obligation for disabled workers) rate for France:



#4.1.7

Fight against harassment and discrimination

ESRS
= S2

CONTEXT AND ISSUES

In line with its commitment to inclusion, fairness and well-being in the workplace, Macopharma is committed to upholding the highest standards in terms of **respect for human rights and the fight against discrimination of any kind**. Employees must be able to report any form of discrimination, harassment or unethical behavior, without fear of direct or indirect sanction, as long as the report is made in good faith.

POLICY

Macopharma is committed to **protecting and respecting the people it works with**, in line with its **Ethical charter and Code of good conduct**: any form of discrimination on the grounds of origin, skin color, disability, trade union membership, religious beliefs, maternity, seniority, military service, gender, age or any other characteristic is **prohibited**. Similarly, any behavior that undermines a **person's dignity**, creates an intimidating, hostile or offensive environment, or unjustifiably interferes with a person's individual performance, is prohibited; in particular, any act of harassment, whatever its form.

ACTION PLANS

1 - Whistleblowing and whistleblower protection system

In accordance with the **Sapin II law** (Law no. 2016-1691), a **whistleblowing platform** was set up in August 2020 to enable anyone, internal or external, to report any inappropriate or illegal behavior within the company, without fear of reprisal. Employees can report any behavior or situation that goes against company policy and contrary to the general interest that they have witnessed: misdemeanors and crimes, environmental as well as personal harm, discrimination, harassment, fraud or any other violation of the law. Alerts are received by the ethics referents and are treated confidentially and anonymously. Depending on the seriousness of the alert, various measures may be taken. An investigation may be set up with the assistance of internal or external experts for the purposes of verifying or processing the alert. In more serious cases, the alert may lead to disciplinary proceedings, the filing of a complaint or other corrective action. experts to verify or process the alert. In more serious cases, the alert may lead to disciplinary proceedings, the filing of a complaint or other corrective actions.

2 - Warning rights

In accordance with current French legislation, employees have the right to alert, as well as the right to alert the CSE. For the French site, the alert rights are as follows:

- **Employees' right to alert**

The French Labor Code defines the right to alert as a situation where employees have reasonable cause to believe that there is a serious and imminent danger to their lives or health.

- **CSE's (economic and social committee) right to alert**

In the event that a member of the CSE observes an infringement of people's rights, physical or mental health, or individual freedoms, he or she must immediately inform the employer. The employer then investigates the matter (without delay) with the CSE member and takes the necessary measures.

For the Tunisian site, administrative procedures are carried out by the HR manager, and then managed in accordance with national legislation in force. For the Polish site, the HR manager may also be called upon to manage alerts.

3 - Sexual harassment referents

In order to **prevent, act on and combat sexist behaviour and sexual harassment in the workplace**, employers must appoint one or two people to whom employees can report inappropriate behaviour. Macopharma has since named to appoint **2 referents** on its French site: an employee representative and an employer representative. Each of these representatives has received training in sexist and sexual harassment, enabling them to recognize the signs and know how to react. As a result, they can act as whistleblowers, and in the event of harassment, a committee can be set up and the CSE can be called in.

4 - Raising employee awareness

The Living Together Week event (see section 4.1.6), organized in November 2023, in favor of diversity and inclusion, also aimed to prevent discrimination by working on the various cognitive biases, behaviors that can harm everyone's well-being, as well as to remind people of Macopharma's anti-discrimination policy.

#4.1.8

Fair, adequate and attractive wages



CONTEXT AND ISSUES

Fair compensation for employees is a key element of a responsible company, and is particularly important in the current inflationary climate. It is also an important element of attractiveness, motivation and **recognition of the work performed**. It includes not only **salaries**, but also a set of social protection and welfare measures that take into account regulations, constraints and the local situation of each site.

Macopharma also believes that all employees, regardless of gender, should receive **equal pay for equal work**. Any difference in salary must be justified by objective criteria such as grade, job profile, skills, etc.

POLICY AND ACTION PLANS

At Macopharma, our salary policy is **consistent with the type of position held and the economic context of the country concerned**. To achieve this, the company uses salary scales defined by collective bargaining agreements and market analyses in all the countries where it operates.

All the Group's employees (excluding the workers category) are also subject to the **salary review** process, which follows on from the appraisals and talent reviews (see section 4.1.3), and through which managers and the HR team steer salary increases. The HR team allocates a budget to each manager, who is then responsible for :

- Making decisions in line with employee appraisals;
- Ensuring that salaries are positioned in relation to the market;
- Providing systematic feedback to employees after salary reviews.

The company is therefore committed to applying **a transparent salary policy** with its employees. In this way, each employee concerned by the salary review receives feedback from his or her manager on the positioning choices made.

Since 2023, for the French site, the HR team has introduced an **ISR (Individual Social Report)**, a document designed to give each employee a clear, confidential and secure overview of the remuneration and benefits received over the previous year.

#4.2

The Group's role in the transfusion chain and its ecosystem

As the issues of economic, social, cultural and civil rights of communities, as well as the rights of indigenous communities, have been identified as non-material, the points identified as material in this section are issues specific to Macopharma, relating to the impact the company seeks to have in its ecosystem with different stakeholders.

#4.2.1

Innovative and effective healthcare solutions

ESRS
=
S3

CONTEXT AND ISSUES

Macopharma belongs to a cutting-edge industrial sector with a **strong societal impact**, requiring continuous innovation. Research into materials and the safety and reliability of devices - essential every drop of blood to reach patients under the best possible conditions - are all areas in which innovation progresses all the faster when it is shared. Macopharma establishes **numerous partnerships** (open innovation) with its customers, the academic world and other laboratories, to develop products and services that best meet the needs of patients and healthcare professionals, while limiting its environmental impact.

Macopharma's growth has historically been driven by **product co-development**. This growth lever remains essential for the years to come. Open innovation implies the interdependence of different players, who must all invest in order to achieve industrial solutions.

REMINDER

2030 Ambition: Design innovative and effective solutions to strengthen the transfusion chain.

2030 objectives:

- One new application per year to feed the innovation pipeline
- One product part of BPS launched per year including at least on patent

POLICY

Macopharma believes in innovation to **achieve its mission** of improving care standards. To this end, the company invests annually in Research & Development (R&D), which will represent 4% of sales by 2023, 311 active patents and 225 active brands.


The company is proud of a number of recent innovations (see below), but aims to stimulate these further by involving all its employees.

ACTION PLANS

Innovation Committee

At the beginning of 2022, a process aimed at **driving innovation**, in line with the field of medical devices and blood treatment solutions (BPS), at Macopharma was initiated via the establishment of an “Innovation Committee (IC)” with the objective of **setting up a process to collect, centralize, identify, evaluate, select and prioritize ideas/opportunities** (IDO) internally. The Committee is made up of several multi-disciplinary experts from different departments, to ensure a cross-functional assessment of the ideas received, and also relies on the involvement of the EXCOM to validate or invalidate its recommendations.

- 47 IDOs received by 12/31/2023, collected from across the Group
- 3 new strategic projects open (i.e. 6% of IDOs received)
- 1 change control open (i.e. 2% of IDOs received)
- 6 incubations currently open for further upstream analysis (i.e. 13% of IDOs received)
- 6 other pre-selected IDOs awaiting incubation (i.e. 13% of IDOs received)
- opening of 2 different methodologies with expert groups (i.e. 4% of IDOs received).



Example of a 2023 innovation: MacoSeal Light

The MacoSeal Light is Macopharma’s **new cordless sealer**. The innovation lies in its **extended battery life**. Its **compact** design, **light weight** and **intuitive button** allow for a wide range of operating configurations.

The MacoSeal Light was designed to increase the device’s capacity, while **optimizing ergonomics** and reducing manual effort. As a result, this innovation helps **minimize Musculoskeletal Disorders (MSD)** for its users. Its light weight facilitates handling, and its wide, flexible press button minimizes pressure on the muscles.

Examples of current projects

Non-DEHP: In order to meet its regulatory requirements and ensure the safety of its users, Macopharma is striving to implement solutions to comply with the REACH regulation banning DEHP from medical devices sold in Europe. Macopharma has made a strong commitment to ban DEHP from all its markets, and has spent over 10 years in research and development to finally find an alternative to DEHT/PAGGS-M (see section 4.3.1).

Replacing mercury lamps: a working group has been set up to look into replacing the mercury lamps used in some of our systems with LEDs.

See also: <https://www.macopharma.com/innovations/>

INDICATORS

→ 3 projects added to the innovation pipeline

#4.2.2

Health education and support for healthcare professionals

ESRS
= S3

CONTEXT AND ISSUES

Macopharma's **Blood processing solutions (BPS)** combine expertise in disposables, equipment, software and processing guidelines to help healthcare professionals obtain safer, higher-quality blood components for the benefit of donors and patients **#EngagedForSolutions**.

One of Macopharma's roles is to **collaborate with stakeholders** in the transfusion chain to improve knowledge and interest in each stage of the chain (best practices, employee awareness programs, etc.). In particular, the company supports healthcare professionals in **optimizing their practices and the use of Macopharma solutions**, as well as improving their medical knowledge for the benefit of patients.

POLICY

Macopharma's policy in this area is in line with its **"engaged for solutions"** pillar: the company offers not just products, but **"complete solutions"** (BPS) to help healthcare professionals optimize their practices and use of products, as well as improve their medical knowledge for the benefit of patients (co-development, education, sharing of best practices, etc.).

ACTION PLANS

1 - BPS & training - Support for healthcare professionals

This support is aimed primarily at **staff at blood banks** around the world who use Macopharma products. The aim of the BPS is to share Macopharma's expertise to guarantee safer, higher quality blood components, more efficiently, for the benefit of staff, donors and patients.

This includes training users of medical devices, equipment and software in their proper use, and sharing best practices to help teams progress in all regions of the world.

All the company's sales teams are trained to deliver the best possible expertise to customers and users.

2 - Congress and ECP academy - Health education

In a spirit of active collaboration with stakeholders, to enhance knowledge and interest in each stage of the transfusion chain, and to promote the exchange of best practices and procedures in the healthcare field, the company acts through 2 main channels:

- **Professional congresses**, in which the company regularly participates worldwide, with oral presentations, posters, workshops, informal exchanges, etc., carried out in collaboration with customers.
- **The ECP (extracorporeal photopheresis) academy**, a series of virtual events aimed at an international audience of doctors, in which the company encourages dialogue and collaboration between clinicians, researchers and other users as part of an educational initiative aimed at creating a healthcare community. Each interested party can then share their experiences, knowledge and expertise on this treatment and the potential options available to patients, which could pave the way for future advances in this field. By staying informed, sharing experiences and prioritizing patient safety, referring physicians and healthcare providers can maximize the potential of Macopharma's ECP treatment and work every day to improve patient outcomes.

#4.2.3

Commitment to local players

ESRS
=
S3

CONTEXT AND CHALLENGES

At each of its sites, Macopharma is committed to supporting projects initiated by local players such as associations, universities and local authorities. This contributes to the company's local presence and brand image, but also to its positive impact outside its own walls and business. This can take the form of charity work or support, both long-standing and one-off.

ACTION PLANS

In 2023, Macopharma pursued its commitment to local communities and players, continuing its historical collaborations or one-off support as described in the non-exhaustive list below:

Blood donor day: every year, the company organizes a day in partnership with the *Etablissement Français du Sang* (EFS), during which every employee is free to come and donate blood during working hours. This year, 304 blood donations were collected worldwide, saving 912 lives.

Partnerships with the Red Cross: Following the conflict in Ukraine, Macopharma organized a new partnership with the Red Cross to help refugees. Thanks to the generosity of its employees, 4,200 euros were raised. Two fundraising campaigns were also organized to help victims of natural disasters in Morocco and Libya. Donations were used to help local populations. A total of 2,095 euros was collected. Macopharma also sent collection kits to Morocco to support local medical teams.

Special Olympics: Special Olympics is an organization dedicated to the self-fulfillment through sport of people living with a mental handicap. The organization, based in France, organizes solidarity races to finance sports and health programs for its mentally handicapped athletes. This year, Macopharma has decided to register 4 teams (16 runners) to take part, with a donation of €3200.

Les papillons blancs de Lille: Created to combat the isolation of families of people with disabilities, and to defend and help create support solutions, the association welcomes, supports and reunites families. A bun sale organized in aid of the association raised €1,856 from employees, with a total donation of €5,558 thanks to Macopharma's contribution. This donation has enabled the development of actions in favor of family caregivers, which have been underway for a number of years: occasional care structures during the week and during the vacations, as well as various actions to support caregivers and welcome disabled people.

Fundacja EVEREST: Nationwide action among companies in Poland supporting disabled people. 12 600 runners took part in the 2023 Corporate Run! 2 200 Companies participated - 92 children were supported.

LA VIE LA VIE: Cooperation with a foundation aiming at increasing awareness about breast cancer and its prevention. In 2023, lecture was made for employees during the Pink October event.

FUNDACJA DLA ROZNORODNOSCI: Association increasing awareness of cancer for men. Lecture to employees during the Movember event.

#4.3

Consumers and end-users

#4.3.1

Patient health and safety

ESRS
= S4

CONTEXT AND ISSUES

One of Macopharma's primary responsibilities is to **guarantee the highest standards of quality, safety and reliability** for its products, to ensure their **perfect innocuousness**. Macopharma must ensure compliance with quality standards, the inactivation of pathogens, the dissemination of best practices, and the optimization of samples and individual components. This is illustrated by its vision to **"push back the boundaries of healthcare by providing integrated solutions to ensure the quality and safety of blood components for every patient in the world"**.

The quality, safety and reliability of our products not only ensure that they are approved and remain on the market, but also guarantee the safety of the patient at the end of the chain. Should a product be defective, vigilance requires that it be withdrawn from the transfusion chain as quickly as possible. This risk is measured by the number of recalls produced each year.


To be compliant with all regulatory processes we have materio and pharmacovigilance numbers accessible 24/7 and indicated on the websites and on the phone answering machine during off hours. On top of this, the company developed a digital platform to enable digital declaration to facilitate customers processes.

REMINDER

2030 Ambition: Providing healthcare products that meet the highest standards of quality and safety.

2030 objectives:

- 100% of our customers converted to phthalate-free products by 2028
- Target no batch recalls
- Target no safety notice advisories from the field

QUALITY POLICY

As quality is a critical factor in patient safety, it defines the titles, standards and benchmarks to be used throughout the product manufacturing and use chain, based on an assessment of risks and solutions to control their impact. This is based on an assessment of risks and solutions to control their impact.

Risks are identified, ex ante, for the design of notices, in order to achieve innocuousness.

To ensure optimal operation, Macopharma's quality approach is supported by a number of tools, structured around **an ISO 13485-certified, annually audited quality management system**, embodied in a set of daily procedures, controls and documentation. A regulatory and **standards watch** is also at the service of the deployment of studies, making it possible to secure certain effects that may be identified in the texts, thus ensuring compliance and anticipation.

One of the issues on which the Group is strongly mobilized is the replacement of plastic substances that are potentially mutagenic, carcinogenic or toxic to reproduction, as well as the question of nanomaterials or animal substances. This has an impact on the way **products are designed** and involves a major R&D and employee training effort. Macopharma also believes that quality is everyone's business, which is why every employee joining the company receives initial quality training to ensure a common base of good practices conducive to a virtuous quality system (see section 4.1.3).

ACTION PLANS

1 - NON-DEHP*

In 2021, European REACH regulations extended the ban on the use of DEHP (plasticizer) in medical devices to 2030, due to the **risk of toxicological effects for human health and the environment**. Macopharma has decided to ban DEHP from all its products, including those not sold on the European market, by 2028.

Until then, DEHP had a number of essential characteristics for the manufacture of products such as blood bags: flexibility, ease of centrifugation, sealing, transport and general handling of blood bags without risk of breakage or product loss. Macopharma has invested almost **10 years in research and development**, in order to successfully complete this crucial and complex transition, by finding an alternative that meets the highest quality standards. The company's commitment is that all its customers will switch to DEHP-free products by 2028, using DEHT/PAGGS-M (di(ethylhexyl) terephthalate/phosphate-adenine-glucose-guanosine-saline-mannitol), an optimal combined solution.

The company is also committed to raising awareness on the subject by communicating with its stakeholders at conferences, symposia, webinars or with its direct distributors.

INDICATORS

In 2023 :

0 batch recalls

2 safety notices

0 major or critical non-conformities detected (quality audit results)

#4.3.2

Continuous access for the greatest number of people



ESRS
= S4

CONTEXT AND ISSUES

As explained above, Macopharma has a responsibility **not to break the transfusion chain**, and to **ensure the availability of its solutions** to enable healthcare professionals to guarantee uninterrupted treatment to every patient. This is illustrated in particular by its commitment to 2030 to take action to make its solutions available to as many patients as possible, but also through its business continuity strategy and policy.

POLICY

With regard to its **business continuity policy**, Macopharma is committed to its customers, employees, shareholders, suppliers, supervisory bodies, etc., to do its utmost to:

- Maintain and perpetuate its activities;
- Respect its contractual commitments;
- Comply with applicable regulations;
- Preserve the company's financial situation;
- Minimize any risk of business interruption.

To achieve this, the company has developed, and continues to improve, **a business continuity management system**, certified to the **international standard ISO 22301**, in order to:

- Integrate business continuity aspects right from the design stage of its products and services;
- Reduce to an acceptable level the processes assessed as critical following an impact and risk analysis;
- Train and raise awareness among its teams of the need to constantly control the risks associated with its processes, in order to maintain business continuity;
- Test its business continuity plan by carrying out real-life exercises to verify its efficiency;
- Determine and monitor relevant performance indicators in order to define avenues for improvement;
- Build a regular communication plan with interested parties.

*DEHP : Di(2-ethylhexyl) phthalate



#5.1

Fighting corruption

ESRS
= G1

CONTEXT AND CHALLENGES

Fighting corruption of all kinds is part of every company's responsibility. It is a cornerstone of **trust** for all our stakeholders. As the healthcare sector is particularly sensitive to **ethical issues**, any practice to the contrary would not only have a major impact on the Group, but also on its customers and partners. To this end, Macopharma is committed to **complying with current legislation**, and has an **assertive anti-corruption policy**.

POLICY

Macopharma materialized its current **"Ethical charter and Code of good conduct"** in 2016, in which it is stated that the company rejects corruption in all its forms. This charter is complemented by its **anti-bribery Code** to ensure that Macopharma's activities are conducted ethically, with integrity and aligned with the **Sapin II law**.

This Code applies to Macopharma's activities, its staff and all the entities within its economic perimeter. Macopharma wishes to associate its counterparties and share its values with them. Any violation of this Code may result in disciplinary measures and the termination of all business relations with counterparties. Macopharma makes no distinction between public and private agents with regard to corruption, which means that bribery **is not tolerated**, whatever the status of the recipient.

The company's anti-corruption policy is based on **three fundamental principles**:

- Macopharma acts with integrity ;
- Macopharma rejects all forms of corruption without exception (defined as: "the act of offering, proposing or promising something of value, material or non-material, in order to obtain an advantage". Thus, a simple agreement between the bribe giver and the bribe taker is sufficient to characterize the offence of bribery and justify criminal prosecution);
- Macopharma ensures that its interactions with customers are transparent and ethical.

ACTION PLAN

1 - Training and awareness-raising

Anti-corruption training for the sales team, previously provided by videoconference or face-to-face, has been reinforced in 2023 by the introduction of e-learning, enabling learning to be better tracked, verified and documented.

Each employee is also made aware of ethics during “initial training” onboarding (see section 4.1.3).

2 - Culture of good internal practices

The company is committed to continuing to disseminate best practices internally, with, for example, the introduction of a specialized platform for processing expense claims, which enables the company's “no gifts” policy to be monitored and applied (this is also accompanied by an e-learning course on the subject).

In 2022 and 2023, onsite events and Digital quiz were organised around Anti-corruption day (Dec 9th) to develop the culture of compliance with all employees.

3 - Third-party audits

A procedure for auditing third parties, by means of questionnaires, in line with the work of the AFA (French Anti-Corruption Agency), has also been put in place.

4 – Whistleblowing platform

The whistleblowing platform, described in section 4.1.7, can also be used by any external or internal party to report corruption that is contrary to the company's commitments.

5 - Risk mapping

A corruption risk map, updated in 2023, identifies the main areas of risk, i.e. relations with distributors and agents, and enables us to be vigilant.

INDICATORS

→ 198 people trained in anti-corruption between 2020 and 2023

→ all sales staff trained in anti-gift law

#5.2

Duty of care in our value chain - responsible purchasing

ESRS
= G1

CONTEXT AND ISSUES

As part of its approach to social responsibility, Macopharma affirms its desire to **involve its stakeholders** and to be a recognized **responsible partner** throughout its value chain. To achieve this, the company is keen to work with suppliers who are in line with its CSR commitments and ambitions.

This involves **rethinking its purchasing strategy**, integrating ESG structuring to assess its partners on all dimensions. However, during its preparatory work, Macopharma did not identify any value chains with critical human rights risks.

2030 Ambition:

Promote business ethics in our relations with all our stakeholders

Objective:

100% of our suppliers audited via our Responsible Purchasing surveys

Payment practices

The Group's payment practices comply with local regulations and contractual conditions. Thanks to a major digital transformation of processes, initiated in 2018, the company has been able to work on making the supplier portfolio and contract signatures more reliable, eliminating paper flows, establishing certificates of origin for logistics, etc.

Responsible purchasing strategy

POLICY & PROCESS

Macopharma expects its suppliers to **act ethically**, respecting **human rights** and the **environment**, and above all to **comply with its quality and HSE criteria**. The company's values with regard to relations with its stakeholders are set out in its Ethical charter (see Appendix C) and in its Declaration against Modern Slavery (see Appendix D).

Before entering into a business relationship with an external service provider, employees should find out about the service provider's reputation and ensure that it complies with legal and contractual provisions and behaves ethically. The service provider is therefore expected to :

- Comply with all specific laws and regulations applicable to our industry when manufacturing products or performing services for us;
- Respect the fundamental principles of the Labor Organization Convention by not using, among other things, child labor or forced labor, and by guaranteeing equal treatment and opportunities to all its employees;
- Inform Macopharma of any conflict of interest likely to affect our relationship before committing to an assignment or service with us;
- Respect the anti-corruption laws in force in their country and applicable to their activity, and confirm this commitment by agreeing to insert appropriate clauses in contracts signed with Macopharma.

The Ethics Charter sets out the principles to which the company adheres, and the next step is to ensure that its suppliers adhere to them in the same way.

Supplier selection

Suppliers are sourced via a **selection process** defined in accordance with financial, quality, HSE and business continuity criteria. Business continuity issues call for careful selection of suppliers, based on quality, cost, lead time, financial status and HSE, to avoid the risk of supply disruption.

In this way, the company has a **mapping of risks** in terms of business continuity and quality, in order to optimize its selection process.

An evaluation and follow-up is also carried out, by sending a questionnaire to its “top suppliers” (80 suppliers) in order to set up a rating and control risks.

Lastly, an **HSE logistics charter** has been drawn up, enabling environmental criteria to be incorporated into contracts with carriers.

In 2024, Macopharma intends to rewrite its purchasing strategy, integrating ESG criteria to a greater extent and thus becoming a truly responsible purchasing strategy, while at the same time working on a responsible purchasing charter to be signed by its suppliers.

In terms of **quality**, the company’s portfolio now complies with European regulations (PE, CMR, MDR, nanoparticles, etc.), ensuring in particular that endocrine-disruptor-free products are placed on the market, in the ultimate interest of patient safety.

As part of its **ISO 14001 management system**, the company has finally integrated environmental criteria into its contracts with major carriers. In this way, they are asked to make commitments to improve their carbon footprint, in the form of a CSR or specific report, choice of engines, eco-driving training for drivers, and so on.

ACTION PLANS

Compliance catalyst

In 2023, to reinforce its monitoring of compliance with the French Sapin II law, the company put 80 suppliers under surveillance using the Compliance catalyst platform. This enables real-time monitoring of compliance issues, thanks to an international database. Eventually, the company aims to formalize and extend this monitoring system to around 500 partners.

Green energy contracts

The company is also working on its energy mix, notably through the introduction of contracts for guaranteed energy produced in France using renewable energies.

Circular economy & Supplier partnerships

The circular economy is an increasingly integrated element in the Group’s purchasing approach, with work to source more and more recycled and recyclable elements, but also in a spirit of partnership with its suppliers.

Examples of joint actions that were carried out in 2023:

- With a label supplier, optimization of cardboard packaging/optimization of pallet transport.
- Deposit system for mandrels (reels) on which labels are wound.
- With Renolit: a joint action plan to use cartons and pallets in a closed loop.

Digitalisation

The purchasing department, in collaboration with other functions, is working on the dematerialization of processes in order to comply with regulatory requirements, but also to reduce the company's impact on the climate and its waste management.

Thus, the transformation is taking place on several points: dematerialization of supplier invoices, a process on which the company is being supported, piloted by the finance functions; dematerialization of the export file (certificate of origin), for the transport logistics/customs management parts etc.; common platform for expense report management (see part 5.1); digital travel booking platform implemented since 2017 in France with the aim of rolling it out to the whole Group (see part 3.1).

Product lifecycle analysis/purchasing process relations

Lastly, purchasing is involved in the product lifecycle analysis working group (see part 3.4), notably by providing the data needed for upstream product analysis such as a "country mapping" of products.

Travel policy update

See section 3.1 Climate change.

Appendices

A_ ESRS CROSS-REFERENCE TABLE

ESRS	Materiality	Related chapter
E1 - Changement climatique	Major	3.1 Climate change
E2 - Pollution		3.2 Fight against pollution
Substances of concern	Critical	3.2 Fight against pollution
Excluding substances of concern	Informational	3.2 Fight against pollution
E3 - Water and Marine Resources	Informational	3.3 Water and marine resources
E4 - Biodiversity and Ecosystems	Not material	N/A
E5 - Resources Use and Circular Economy	Critique	3.4 Circular economy and waste management
S1 - Own Workforce		4.1 Our employees
Social dialogue	Major	4.1.2 Social dialogue
Training and skills development	Major	4.1.3 Training and professional development
Health and safety at work	Major	4.1.4 Health and safety
Quality of life at work	Major	4.1.5 Quality of life at work
Equity & Diversity	Opportune	4.1.6 Equity, equal opportunity, inclusion
Harassment and discrimination	Informational	4.1.7 Fight against harassment and discrimination
Decent wages	Informational	4.1.8 Fair, adequate and attractive wages
S2 - Workers in the Value Chain	Major	5.2 Responsible purchasing
S3 - Affected Communities		4.2 The Group's role in the transfusion chain and its ecosystem
Open innovation	Critical	4.2.1 Innovative and effective healthcare solutions
Health education and support for healthcare professionals	Informational	4.2.2 Health education and support for healthcare professionals
Communities engagement	Informational	4.2.3 Commitment to local stakeholders
S4 - Consumers and End-users		4.3 Consumers and end-users
Patient safety	Critical	4.3.1 Patient health and safety
Continuous access to solutions	Critical	4.3.2 Continuous access for the greatest number of people
G1 - Business Conduct		
Corruption	Critical	5.1 Fight against corruption
Supplier relations and selection / payment practices	Major	5.2 Responsible purchasing


Appendices

PDF INTERACTIF

B_ HSE POLICY

C_ ETHICAL CHARTER AND CODE OF CONDUCT

D_ DECLARATION AGAINST MODERN SLAVERY



We support life

www.macopharma.com